Journal: Frontiers in immunology

Article Title: Immunometabolic interference between cancer and COVID-19.

doi: 10.3389/fimmu.2023.1168455

Figure Lengend Snippet: FIGURE 9 Flow cytometry analysis of NAMPT and NAD-dependent enzymes in the different patient cohorts. Box-and-whisker plots representing FACS quantification of (A) NAMPT, (B) pSIRT1, (C) CD38, (D) CD39 and (E) PARP expression in the indicated immune cell populations (CD3+ T cells, CD19+

Article Snippet: Cells were incubated with the following antihuman antibodies for 20 min at 4°C: CD33 PerCP Cy5.5 (WM53) (0.6:100, Biolegend cat No. 303402), CD14 BV650 (M5E2) (1.25:100, Biolegend cat. No. 301835), CD16 BV711 (3G8) (0.3:100, Biolegend cat. No. 302044), HLA-DR BV421 (L243) (1.25:100, Biolegend Cat No. 307636), CD15 BV786 (HI98) (1.25:100, BD Biosciences cat. No. 563838), CD11c BUV661 (B-ly6) (0.6:100, BD Biosciences cat. No. 612968), CD123 BUV395 (7G3) (0.6:100, BD Biosciences cat. No. 564195), CD38 PE-Cy7 (HIT2) (1.25:100, Invitrogen cat. No. 25- 0389-42), CD39 PE (MZ18-23C8) (0.6:100, MACSMiltenyi Biotec Inc. cat. No.130-118-668), CD39 FITC (MZ18-23C8) (1.25:100, MACS Miltenyi Biotec Inc. cat. No. 130-125-113), CD3 BV650 (OKT3) (1.25:100, Biolegend cat. No.317324), CD4 BV570 (OKT4) (2.5:100, Frontiers in Immunology 03 Biolegend cat. No. 317445), CD8 BV786 (RPA-T8) (0.6:100, BD Biosciences cat. No. 557085), CD19 AF-700 (HIB19) (2.5:100, BD Biosciences cat. No. 561031), CD45RA APC-Cy7 (HI100) (1.25:100, BD Biosciences cat. No. 560674), CD45RO BUV395 (UCHL1) (1.25:100, BD Biosciences 564292), CD27 PE-Cy5 (O323) (1.25:100, Invitrogen cat. No. 15295964), CD16 BV605 (3G8) (0.6:100, Biolegend 302040), CD3 BUV496 (UCHT1) (1.25:100, BD Biosciences cat. No. 612940), CD66b PE-Cy7(G10F5) (0.6:100 Biolegend cat. No. 305116) and IgD FITC (IA6-2) (1.25:100, Invitrogen cat. No. 11-9868-42).

Techniques: Flow Cytometry, Whisker Assay, Expressing

Journal: Frontiers in Immunology

Article Title: Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging

doi: 10.3389/fimmu.2024.1383932

Figure Lengend Snippet: Immunophenotyping panel for multiplexed tissue imaging of cancer.

Article Snippet: CD39 , REA739 , 50 , 130-110-650 , PE , Miltenyi Biotec.

Techniques: Imaging

Journal: Frontiers in Immunology

Article Title: Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging

doi: 10.3389/fimmu.2024.1383932

Figure Lengend Snippet: Cellular neighborhood analysis of PD1 high/low T cells in the tumor margin and core. (A–D) Topology of PD1 high (left) and PD1 low (right) T cells and their cellular neighborhood within a 5 µm range. (A, B) represent tumor margin and (C, D) show tumor core areas. Cell types showing different distribution patterns around PD1 high and PD1 low T cells (mDCs, M1-like M, M2-like M, MDSCs, Fibroblasts, vessels, tumor cells) are highlighted by arrowheads. (E, F) Quantification of cells in a 5 µm range around of PD1 high/low T cells for tumor margin and tumor core, (E) represents immune cells and (F) stroma/tumor cells. (G) Violin plots for expression levels of eight immune-modulating markers (CD112, CD155, CD276, CD39, CD73, IDO, PD-L1, and VISTA) for the most important immune and tumor cells around PD1 high/low T cells in the tumor core area. Violin plots for tumor margin are shown in Supplementary Figure S5E . Depicted markers and annotated cell types as indicated by the color code. ROI sizes: Tumor margin (ROI15) and tumor core (ROI16): 975 x 769 µm.

Article Snippet: CD39 , REA739 , 50 , 130-110-650 , PE , Miltenyi Biotec.

Techniques: Expressing

Journal: Heliyon

Article Title: Pharmacodynamics of Sishen decoction in relieving rheumatoid arthritis: Chemical composition, regulatory pathway and online prediction simulation

doi: 10.1016/j.heliyon.2024.e37257

Figure Lengend Snippet: SSD treatment ameliorated RA rats. Representative images of hind paws from different groups and changes in foot circumference. Hematoxylin eosin staining and immunohistochemical staining (CD31, CD39, CD73, CCR6 and IL1R1) of knee joint synovial slices. * P < 0.05, ** P < 0.01 vs Model group.

Article Snippet: Additionally, antibodies for IL1R1, CD39, CD73, and CCR6 were obtained from Bosterbio in Wuhan, China.

Techniques: Staining, Immunohistochemical staining

Journal: Biomolecules

Article Title: Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response

doi: 10.3390/biom14010001

Figure Lengend Snippet: Flow cytometric analysis of CD39 and CD73 on monocytes, CD8, CD4, Treg, B, and NK cells from peripheral blood of untreated RA patients (RA) and healthy controls (C). Representative dot plots for surface expression of CD39 and CD73 and frequencies of different subpopulations (CD39 + CD73 + , CD39 + CD73 − , CD39 − CD73 + , and CD39 − CD73 − ). Data are expressed as means and SD (standard deviation) of the percentage of the corresponding population (CD4 + T cells, CD8 + T cells, B cells, NK, lymphocytes, and monocytes). In the case of Treg (CD4 + CD25 high CD127 low ) the percentage is expressed for total CD4 + T cells. An unpaired t -test was used to compare the percentages in the RA and C groups.

Article Snippet: The PBMCs were stained with the following monoclonal antibodies: anti-human CD3-Viogreen (Miltenyi Biotec GmBh), CD39-Fitc and CD73-PE (BD Biosciences), and CD8-PECy7 (Biolegend).

Techniques: Expressing, Standard Deviation

Journal: Biomolecules

Article Title: Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response

doi: 10.3390/biom14010001

Figure Lengend Snippet: Correlations between some subsets and clinical parameters. Correlation plots corresponding to relationships between disease activity indexes and the percentages of CD8 + CD39 − CD73 + , CD8 + CD39 − CD73 − , Treg CD39 + CD73 + , Treg CD39 − CD73 − or B CD39 − CD73 − subsets in RA patients at baseline. Only the plots with a tendency line presented a significative correlation applying Pearson’s test.

Article Snippet: The PBMCs were stained with the following monoclonal antibodies: anti-human CD3-Viogreen (Miltenyi Biotec GmBh), CD39-Fitc and CD73-PE (BD Biosciences), and CD8-PECy7 (Biolegend).

Techniques: Activity Assay

Journal: Biomolecules

Article Title: Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response

doi: 10.3390/biom14010001

Figure Lengend Snippet: Correlations between subsets and clinical parameters ( a ) Correlograms corresponding to R-RA (n = 20) and NR-RA (n = 10) patients. Squares marked with a black border in correlogram indicate significant correlations observed in R-RA, but not in NR-RA patients. ( b ) Correlation plots illustrating the relationship between disease activity indexes and the percentage of Treg CD39 + CD73 − , CD8 + CD39 − CD73 + , CD8 + CD39 − CD73 − , B CD39 − CD73 − , B CD39 − CD73 + or B CD39 + CD73 − subsets in R-RA patients at baseline. p = 0.05 *, p = 0.01 ** and p = 0.001 ***.

Article Snippet: The PBMCs were stained with the following monoclonal antibodies: anti-human CD3-Viogreen (Miltenyi Biotec GmBh), CD39-Fitc and CD73-PE (BD Biosciences), and CD8-PECy7 (Biolegend).

Techniques: Activity Assay

Journal: Biomolecules

Article Title: Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response

doi: 10.3390/biom14010001

Figure Lengend Snippet: Effects of stimulation on CD39 and CD73 expression. ( a ) Representative dot plots for surface expression of CD39 and CD73 on CD4 + T and CD8 + T cells on PBMCs from Cs before culture and after 72 h cultured without beads (medium) or with beads (medium + beads). Additionally, PBMCs from Cs were cultured with IL-6, both without beads (IL-6) and with beads (IL-6 + beads). ( b ) Percentages of the four subsets of CD4 + T and CD8 + T cells from PBMCs cultured for 72 h either with anti-CD3/CD28 beads (empty dots) or without beads (full dots). ( c ) Percentages of subsets cultured under the same conditions, but with IL-6. The double-negative subset in CD4 + T and CD8 + T cells as well as the CD8 + CD39 − CD73 + subset are represented in the right axes. The Wilcoxon signed-rank test was applied in comparisons.

Article Snippet: The PBMCs were stained with the following monoclonal antibodies: anti-human CD3-Viogreen (Miltenyi Biotec GmBh), CD39-Fitc and CD73-PE (BD Biosciences), and CD8-PECy7 (Biolegend).

Techniques: Expressing, Cell Culture

Journal: Biomolecules

Article Title: Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response

doi: 10.3390/biom14010001

Figure Lengend Snippet: Effects of stimulation on CD39 and CD73 expression, and IFNγ production in CD4 + T and CD8 + T cells. The PBMCs from Cs (gray symbols) and RA patients (black symbols) were cultured for 72 h with beads and with (triangles) or without IL-6 (dots). The percentages of IFNγ-producing cells in CD4 + T (CD4 + IFN + ) and CD8 + T cells (CD8 + IFN + ) were categorized into two groups based on their expression of CD39 (CD39 + and CD39 − ) or CD73 (CD73 + and CD73 − ). In all plots, symbols colored in red correspond to NR-RA patients. Paired t -tests were applied in comparisons between subsets from C or RA patients and unpaired t -test to compare equivalent subsets in C with RA patients.

Article Snippet: The PBMCs were stained with the following monoclonal antibodies: anti-human CD3-Viogreen (Miltenyi Biotec GmBh), CD39-Fitc and CD73-PE (BD Biosciences), and CD8-PECy7 (Biolegend).

Techniques: Expressing, Cell Culture

Journal: Frontiers in Immunology

Article Title: Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?

doi: 10.3389/fimmu.2024.1406250

Figure Lengend Snippet: Phenotype of effector T reg cells in human PDAC. Effector T regs – characterised by the expression of FOXP3, CD25, TIGIT, CTLA-4, ICOS, CD39, and CCR8 – are activated by sustained TCR stimulation with abundant self- and quasi-self-antigens and stabilised by expression of the Helios transcription factor. These cells exhibit potent immunosuppressive capacity within the PDAC TME, where they exist in close proximity to CD8 + T lymphocytes. Specifically, they express co-inhibitory molecules (e.g., CTLA-4, TIGIT, ICOS); convert ATP to immunosuppressive adenosine via ectoenzymes that remain catalytically active after cell-death (CD39 and CD73); secrete immunosuppressive cytokines (e.g., IL-10, IL-35, TGF- β ) and granzymes that lyse CD8 + T eff cells; and sequester IL-2 that is required for T eff cell activation.

Article Snippet: TTX-030 , Trishula Therapeutics/AbbVie , Anti-CD39 monoclonal antibody , Phase II, + chemotherapy +/- budigalimab (anti-PD-1), in patients with metastatic PDAC , NCT06119217.

Techniques: Expressing, Activation Assay

Journal: Frontiers in Immunology

Article Title: Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?

doi: 10.3389/fimmu.2024.1406250

Figure Lengend Snippet: T reg -targeted immunotherapies in current development (as of 01/05/2024).

Article Snippet: TTX-030 , Trishula Therapeutics/AbbVie , Anti-CD39 monoclonal antibody , Phase II, + chemotherapy +/- budigalimab (anti-PD-1), in patients with metastatic PDAC , NCT06119217.

Techniques: Recombinant